Medication

Several innovative controlled release drugs and nutraceuticals are currently in development by APeT. Present focus is on the following:

Nic‐12 (Nicotinamide. NR, NMN, NA are following soon), APeT’s lead novel drug treatment for ASD patients that does not have the side effects of standard of care drugs and treats comorbidities as well
Coverall‐12, a Nic‐12 accompanying special formulated nutraceutical based on results acquired through APeT diagnostics. The specific nutrients in Coverall‐12 are required for key metabolic pathway steps regulated by Nic‐12 and improve patient outcome
Cannabinoid formulations (Hemp oil, CBD, CBC, CBG, THCV, CBN,…): IBS, IBD, pain relief, antiinflammatory, anti‐aging
Serotonin 2A receptor agonists (Psilocybin, LSD, DMT, MDMA,…): anti‐aging, restoring brain function, boosting creativity, anxiety, depression, PTSD, anorexia, sleep disorders, neurodegenerative diseases like Alzheimer and Parkinson
ConstaDopa, APeT’s new Parkinson levodopa‐controlled release drugTolerase L and Tolerase G for Lactose and gluten intolerance: Take one capsule in the morning and don’t worry about what you eat the rest of the day
Tolerase L and Tolerase G for Lactose and gluten intolerance: Take one capsule in the morning and don’t worry about what you eat the rest of the day
New proprietary compounds from multinational license partners